Javier Cortés
Breast oncologist who led DESTINY-Breast03 and DESTINY-Breast09, the trials that made Enhertu the HER2-positive standard.
Javier Cortés was principal investigator of DESTINY-Breast03 (T-DXd versus T-DM1) and DESTINY-Breast09 (T-DXd plus pertuzumab first-line), and co-led CLEOPATRA and PHERGain. He built his career at Vall d'Hebron and now leads the International Breast Cancer Center in Barcelona.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03) | NEJM | 2022 |
For HER2-positive metastatic breast cancer that has progressed after trastuzumab and a taxane, trastuzumab deruxtecan is now the standard second-line treatment and T-DM1 has moved later in the sequence. The benefit is large enough that ADC design, not just the target, is understood to be what matters. Patients need lung monitoring because of the risk of pneumonitis.
For stage II-III triple-negative breast cancer, chemotherapy plus pembrolizumab before surgery and pembrolizumab alone afterwards is now the standard approach worldwide, and the survival gain is real, not just a surrogate. It does not apply to stage I disease or to hormone-receptor-positive or HER2-positive cancers. The price is a year of immunotherapy with a meaningful chance of a permanent endocrine side effect such as hypothyroidism or adrenal insufficiency.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.